[Pharmaceutical application of cyclodextrins as multi-functional drug carriers]
- PMID: 15577263
- DOI: 10.1248/yakushi.124.909
[Pharmaceutical application of cyclodextrins as multi-functional drug carriers]
Abstract
Owing to the increasingly globalized nature of the cyclodextrin (CyD)-related science and technology, development of the CyD-based pharmaceutical formulation is rapidly progressing. The pharmaceutically useful CyDs are classified into hydrophilic, hydrophobic, and ionic derivatives. Because of the multi-functional characteristics and bioadaptability, these CyDs are capable of alleviating the undesirable properties of drug molecules through the formation of inclusion complexes or the form of CyD/drug conjugates. This review outlines the current application of CyDs in drug delivery and pharmaceutical formulation, focusing on the following evidences. 1) The hydrophilic CyDs enhance the rate and extent of bioavailability of poorly water-soluble drugs. 2) The amorphous CyDs such as 2-hydroxypropyl-beta-CyD are useful for inhibition of polymorphic transition and crystallization rates of drugs during storage. 3) The delayed release formulation can be obtained by the use of enteric type CyDs such as O-carboxymethyl-O-ethyl-beta-CyD. 4) The hydrophobic CyDs are useful for modification of the release site and/or time profile of water-soluble drugs with prolonged therapeutic effects. 5) The branched CyDs are particularly effective in inhibiting the adsorption to hydrophobic surface of containers and aggregation of polypeptide and protein drugs. 6) The combined use of different CyDs and/or pharmaceutical additives can serve as more functional drug carriers, improving efficacy and reducing side effects. 7) The CyD/drug conjugates may provide a versatile means for the constructions of not only colonic delivery system but also site-specific drug release system, including gene delivery. On the basis of the above-mentioned knowledge, the advantages and limitations of CyDs in the design of advanced dosage forms will be discussed.
Similar articles
-
Design and evaluation of cyclodextrin-based drug formulation.Chem Pharm Bull (Tokyo). 2004 Aug;52(8):900-15. doi: 10.1248/cpb.52.900. Chem Pharm Bull (Tokyo). 2004. PMID: 15304981 Review.
-
[Novel approach of cyclodextrin-based pharmaceutical formulation].Yakugaku Zasshi. 2012;132(1):85-105. doi: 10.1248/yakushi.132.85. Yakugaku Zasshi. 2012. PMID: 22214584 Review. Japanese.
-
[Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].Yakugaku Zasshi. 1993 Jun;113(6):425-37. doi: 10.1248/yakushi1947.113.6_425. Yakugaku Zasshi. 1993. PMID: 8355145 Review. Japanese.
-
Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.Pharm Res. 2001 Nov;18(11):1578-85. doi: 10.1023/a:1013034615464. Pharm Res. 2001. PMID: 11758766
-
Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.Chem Pharm Bull (Tokyo). 1989 Apr;37(4):1059-63. doi: 10.1248/cpb.37.1059. Chem Pharm Bull (Tokyo). 1989. PMID: 2766408
Cited by
-
Ergosterol treatment leads to the expression of a specific set of defence-related genes in tobacco.Plant Mol Biol. 2006 Sep;62(1-2):43-51. doi: 10.1007/s11103-006-9002-5. Epub 2006 Aug 10. Plant Mol Biol. 2006. PMID: 16900324
-
Comparative Analysis of γ-Cyclodextrin, Perilla Oil, and Their Inclusion Complexes on Liver Injury and Dyslipidemia Associated with Elevated Gastrointestinal 12-Hydroxylated Bile Acid Levels.Molecules. 2025 Jan 13;30(2):281. doi: 10.3390/molecules30020281. Molecules. 2025. PMID: 39860151 Free PMC article.
-
Recent Findings Concerning PAMAM Dendrimer Conjugates with Cyclodextrins as Carriers of DNA and RNA.Sensors (Basel). 2009;9(8):6346-61. doi: 10.3390/s90806346. Epub 2009 Aug 17. Sensors (Basel). 2009. PMID: 22454589 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources